Publications by authors named "P Thiyagarajah"
Article Synopsis
- In the phase 3 PACIFIC trial, durvalumab was found to significantly extend progression-free survival (PFS) and overall survival (OS) in patients with advanced lung cancer who were untreated after chemoradiotherapy.
- A notable proportion of patients experienced symptomatic radiation pneumonitis (PRP), with 19.8% in the durvalumab group and 14.1% in the placebo group, though severe cases were rare.
- Factors such as being treated in Asia, having stage IIIA disease, and certain performance statuses increased the risk of G2+PRP, but the effectiveness of durvalumab persisted regardless of these side effects.
Introduction: Consolidation durvalumab (the "PACIFIC regimen") is standard of care for patients with unresectable stage III NSCLC who have not progressed after chemoradiotherapy, on the basis of data from the phase 3 placebo-controlled PACIFIC study (NCT02125461). Nevertheless, the benefit of immunotherapy in patients with stage III EGFR-mutant (EGFRm) NSCLC is not well characterized. Here, we report a post hoc exploratory efficacy and safety analysis from a subgroup of patients with EGFRm NSCLC from the PACIFIC.
View Article and Find Full Text PDFArticle Synopsis
- In the PACIFIC trial, it was found that about 25% of patients treated with durvalumab experienced immune-mediated adverse events (imAEs), mostly mild, with only 3.4% facing severe cases.
- The study analyzed the incidence and management of imAEs, focusing on both pneumonitis and non-pneumonitis events, revealing that these events were more common in the durvalumab group than in those on placebo.
- Most imAEs, particularly pneumonitis and non-pneumonitis, occurred within three months of starting treatment, and were generally manageable through corticosteroids and other therapies.
Purpose: The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.
View Article and Find Full Text PDFIntroduction: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end points of overall survival (OS) (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53-0.
View Article and Find Full Text PDF